Vistagen Therapeutics, Inc. · NASDAQ:VTGN
Vistagen Therapeutics — Technical Presentation (June 2026)
8 slides from Vistagen Therapeutics's technical presentation, Jun 30, 2026
Slide 1: PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol Topline Results
NASDAQ: VTGN PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol Topline Results Tuesday, June 30, 2026 8:30 a.m. EST
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the federal securities laws. These statements include, without limitation, statements regarding Vistagen's interpretation of the PALISADE-4 clinical data and additional analyses; the potential significance of findings observ
Slide 3: Vistagen Team Conference Call Participants
Vistagen Team Conference Call Participants Shawn K. Singh, J.D. President and Chief Executive Officer Joshua Prince, MBA Chief Operating Officer Mark A. McPartland Senior Vice President Investor Relations Angel S. Angelov, MD., MBA Chief Medical Officer
Slide 4: PALISADE-4 Full Population Primary Endpoint: Change in LS Mean SUDS Score vs Placebo
PALISADE-4 Full Population Primary Endpoint: Change in LS Mean SUDS Score vs Placebo Did not meet the primary endpoint (p=0.427) N=71 N=70 N=61 N=132 N=199 34.9 23.9 31.5 20.3 0 5 10 15 20 25 30 35 40 Visit 2 Visit 3 Mean change from baseline by Visit Fasedienol Placebo 9.5 11.4 0 5 10 15 20 P=0.427
Slide 5: PALISADE-4 Full Population Secondary Endpoints: CGI-I and PGI-C % responders
29.9% 34.7% 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% P=ns CGI-I % Responders (Rating of 1 or 2) Fasedienol Placebo PALISADE-4 Full Population Secondary Endpoints: CGI-I and PGI-C % responders at V3 Did not meet secondary endpoints; Divergent directionality of CGI-I and PGI-C % responders N=117 N=121 Sc
Slide 6: Post Hoc Analysis of PALISADE-4 in Very Severe SAD Subjects
Post Hoc Analysis of PALISADE-4 in Very Severe SAD Subjects Statistically Significant LS Mean SUDS Change vs Placebo (P=0.036) Excluding: one site for unreliable data; subjects with V1 LSAS <95; and subjects with ceiling SUDS values1 All P-Values calculated using ANCOVA model per PALISADE-4 SAP 32.1
Slide 7: Post Hoc Analysis of Pooled Trials in Very Severe SAD Subjects
Post Hoc Analysis of Pooled Trials in Very Severe SAD Subjects Excluding: one site each from PAL-4 and PAL-1 for unreliable data; subjects with V1 LSAS <95; and subjects with ceiling SUDS values1 (All P-Values calculated using two-tailed t tests) N= 70 N= 71-16.6 -16.0 -14.6 -9.5 -10.3 -10.1 PALISAD
Slide 8: Thank you! Contact Us
Thank you! Contact Us Investor Relations: IR@vistagen.com Media Relations: Media@vistagen.com NASDAQ: VTGN
Vistagen Therapeutics — Technical Presentation (June 2026) on 6ix